Niels-Christian Reichardt

Niels-Christian Reichardt

Auto-generated profile, based on publicly available information

Niels-Christian Reichardt

Glycotechnology Laboratory, CIC biomaGUNE, Paseo Miramón 182, 20014 San Sebastián, Spain

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2018 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
CWCharles Williams
Charles Williams
FRFelix Royo
Felix Royo
OAOier Aizpurua‐Olaizola
Oier Aizpurua‐Olaizola
RPRaquel Pazos
Raquel Pazos
GBGeert‐Jan Boons
Geert‐Jan Boons
JFJuan M Falcon-Perez
Juan M Falcon-Perez
It is now acknowledged that extracellular vesicles (EVs) are important effectors in a vast number of biological processes through intercellular transfer of biomolecules. Increasing research efforts in the EV field have yielded an appreciation for the potential role of glycans in EV function. Indeed, recent reports show that the presence of glycoconjugates is involved in EV biogenesis, in cellular recognition and in the efficient uptake of EVs by recipient cells. It is clear that a full understanding of EV biology will require researchers to focus also on EV glycosylation through glycomics approaches. This review outlines the major glycomics techniques that have been applied to EVs in the context of the recent findings. Beyond understanding the mechanisms by which EVs mediate their physiological functions, glycosylation also provides opportunities by which to engineer EVs for therapeutic and diagnostic purposes. Studies characterising the glycan composition of EVs have highlighted glycome changes in various disease states, thus indicating potential for EV glycans as diagnostic markers. Meanwhile, glycans have been targeted as molecular handles for affinity‐based isolation in both research and clinical contexts. An overview of current strategies to exploit EV glycosylation and a discussion of the implications of recent findings for the burgeoning EV industry follows the below review of glycomics and its application to EV biology.

15 August 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CWCharles Williams
Charles Williams
RPRaquel Pazos
Raquel Pazos
FRFelix Royo
Felix Royo
EGEsperanza Gónzalez
Esperanza Gónzalez
MRMeritxell Roura-Ferrer
Meritxell Roura-Ferrer
JFJuan M Falcon-Perez
Juan M Falcon-Perez
Extracellular vesicles (EVs) are important mediators of cell-cell communication in a broad variety of physiological contexts. However, there is ambiguity around the fundamental mechanisms by which these effects are transduced, particularly in relation to their uptake by recipient cells. Multiple modes of cellular entry have been suggested and we have further explored the role of glycans as potential determinants of uptake, using EVs from the murine hepatic cell lines AML12 and MLP29 as independent yet comparable models. Lectin microarray technology was employed to define the surface glycosylation patterns of EVs. Glycosidases PNGase F and neuraminidase which cleave N-glycans and terminal sialic acids, respectively, were used to analyze the relevance of these modifications to EV surface glycans on the uptake of fluorescently labelled EVs by a panel of cells representing a variety of tissues. Flow cytometry revealed an increase in affinity for EVs modified by both glycosidase treatments. High-content screening exhibited a broader range of responses with different cell types preferring different vesicle glycosylation states. We also found differences in vesicle charge after treatment with glycosidases. We conclude that glycans are key players in the tuning of EV uptake, through charge-based effects, direct glycan recognition or both, supporting glycoengineering as a toolkit for therapy development.

10 January 2013 in Chemical Society Reviews
Verified
Journal Article
Closed access
PDF file
NRNiels C. Reichardt
Niels C. Reichardt
MMManuel Martín-Lomas
Manuel Martín-Lomas
SPSoledad Penadés
Soledad Penadés
Glyconanotechnology can be seen as the synergy between nanotechnology and glycan related biological and medical problems. This review focuses on the crosstalk of glycoscience and nanotechnology, which will lead to a deeper understanding of glycobiology and to new glyco-materials with improved design and synergistic properties derived from glycoscience concepts for future nanodevices. It is intended to provide the glycoscientist with an application-oriented entry to the possibilities of nanotechnologies for his research. The most recent examples of glyco-nanomaterials as multivalent scaffolds for drug delivery, enzyme inhibition and for vaccine development, glycan functionalized quantum dots and nanoparticles in molecular imaging, biosensors for lectin/glycan detection based on nanomaterials, and new concepts for the affinity separation and analysis using nanomaterials or nanotools are revised.

10 June 2020 in Chemical Society Reviews
Verified
Journal Article
Open access
PDF file
BLBruno Linclau
Bruno Linclau
AAAna Arda
Ana Arda
NRNiels-Christian Reichardt
Niels-Christian Reichardt
MSMatthieu Sollogoub
Matthieu Sollogoub
LULuca Unione
Luca Unione
Jesus Jimenez-BarberoJesus Jimenez-Barbero
Jesus Jimenez-Barbero
Fluorinated carbohydrates have become indispensable in glycosciences. This contribution provides an overview of how fluorine introduction modifies physical and chemical properties of carbohydrates along with selected examples of its applications.

12 November 2019 in Metabolites
Verified
Journal Article
Open access
PDF file
CWCharles Williams
Charles Williams
MPMari Palviainen
Mari Palviainen
NRNiels-Christian Reichardt
Niels-Christian Reichardt
PSPia Siljander
Pia Siljander
JFJuan M Falcon-Perez
Juan M Falcon-Perez
Cell-secreted extracellular vesicles (EVs) have rapidly gained prominence as sources of biomarkers for non-invasive biopsies, owing to their ubiquity across human biofluids and physiological stability. There are many characterisation studies directed towards their protein, nucleic acid, lipid and glycan content, but more recently the metabolomic analysis of EV content has also gained traction. Several EV metabolite biomarker candidates have been identified across a range of diseases, including liver disease and cancers of the prostate and pancreas. Beyond clinical applications, metabolomics has also elucidated possible mechanisms of action underlying EV function, such as the arginase-mediated relaxation of pulmonary arteries or the delivery of nutrients to tumours by vesicles. However, whilst the value of EV metabolomics is clear, there are challenges inherent to working with these entities—particularly in relation to sample production and preparation. The biomolecular composition of EVs is known to change drastically depending on the isolation method used, and recent evidence has demonstrated that changes in cell culture systems impact upon the metabolome of the resulting EVs. This review aims to collect recent advances in the EV metabolomics field whilst also introducing researchers interested in this area to practical pitfalls in applying metabolomics to EV studies.

23 February 2015 in ACS Chemical Biology
Verified
Journal Article
Closed access
KBKatarzyna Brzezicka
Katarzyna Brzezicka
BEBegoña Echeverria
Begoña Echeverria
SSSonia Serna
Sonia Serna
ADAngela van Diepen
Angela van Diepen
CHCornelis H. Hokke
Cornelis H. Hokke
NRNiels-Christian Reichardt
Niels-Christian Reichardt